|1.||Bradshaw, T D: 4 articles (01/2009 - 01/2002)|
|2.||Leong, C-O: 2 articles (01/2009 - 02/2003)|
|3.||Farmer, P B: 2 articles (01/2009 - 02/2003)|
|4.||Stevens, M F G: 2 articles (01/2009 - 02/2003)|
|5.||Gaskell, M: 2 articles (01/2009 - 02/2003)|
|6.||Hose, Curtis: 2 articles (08/2006 - 09/2004)|
|7.||Monks, Anne: 2 articles (08/2006 - 09/2004)|
|8.||Stevens, Malcolm F G: 2 articles (12/2004 - 09/2004)|
|9.||Bradshaw, Tracey D: 2 articles (12/2004 - 09/2004)|
|10.||Westwell, A D: 2 articles (04/2004 - 01/2002)|
02/10/2003 - "Inherently resistant MDA-MB-435 breast carcinoma cells incurred no DNA damage upon exposure to Phortress (< or = 10 microM, 24 h). "
09/01/2004 - "Phortress (the dihydrochloride salt of the lysylamide prodrug of 2-(4-amino-3-methylphenyl)-5-fluoro-benzothiazole (5F 203)) is an experimental antitumor agent with potent and selective activity against human-derived carcinomas of breast, ovarian and renal origin. "
09/01/2004 - "In the present study, the antitumor efficacy of Phortress has been compared with that of doxorubicin (Dox) in nine human-derived mammary carcinoma xenograft models, cultivated subcutaneously in the flanks of nude mice. "
09/01/2004 - "The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models."
|2.||Colorectal Neoplasms (Colorectal Cancer)
11/01/2006 - "The efficacy of Phortress against colorectal cancer cells in the current study confirms that the spectrum of activity of Phortress may be wider than previously thought."
11/01/2006 - "In vitro cytotoxicity of Phortress against colorectal cancer."
11/01/2006 - "As expected, Phortress was cytotoxic to MCF7 breast cancer cells, but unexpectedly, Phortress was also potent against colorectal cancer cells in clonogenic survival and cell growth (growth curves but not MTS assay) end-points. "
|3.||Breast Neoplasms (Breast Cancer)
08/01/2006 - "These results confirm that NAG-1 suppresses tumor growth, and its in vivo expression can be controlled by treating mice with anticancer drugs, such as Phortress. "
12/01/2004 - "By conducting SCGE, tumor sensitivity to Phortress, an agent currently undergoing clinical evaluation, may be determined."
12/01/2004 - "In vivo, Phortress-sensitive and Phortress-resistant tumor cells were distinct; moreover, DNA damage in xenografts, following treatment of mice with Phortress, could be determined. "
12/01/2004 - "Following treatment of xenograft-bearing mice and mice possessing hollow fiber implants containing MCF-7 or MDA-MB-435 cells with Phortress (20 mg/kg, i.p., 24 hours), tumor cells and xenografts were recovered for analyses by SCGE. "
08/01/2006 - "Treatment of the mice with Phortress, the prodrug of 5F203, increased the in vivo expression of NAG-1 as measured by real-time reverse transcription-polymerase chain reaction from RNA obtained by needle biopsy, and the expression correlated with a reduction of tumor volume. "
|5.||Kidney Neoplasms (Kidney Cancer)
|4.||Cytochrome P-450 CYP1A1 (CYP1A1)
|5.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|8.||RNA (Ribonucleic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)